Skip to main content

4 Result(s)

within Mai Abdusamad Remove this filter

and

  1. No Access

    Article

    Phosphate dysregulation via the XPR1–KIDINS220 protein complex is a therapeutic vulnerability in ovarian cancer

    Despite advances in precision medicine, the clinical prospects for patients with ovarian and uterine cancers have not substantially improved. Here, we analyzed genome-scale CRISPR–Cas9 loss-of-function screens...

    Daniel P. Bondeson, Brenton R. Paolella, Adhana Asfaw, Michael V. Rothberg… in Nature Cancer (2022)

  2. No Access

    Article

    Aneuploidy renders cancer cells vulnerable to mitotic checkpoint inhibition

    Selective targeting of aneuploid cells is an attractive strategy for cancer treatment1. However, it is unclear whether aneuploidy generates any clinically relevant vulnerabilities in cancer cells. Here we mapped ...

    Yael Cohen-Sharir, James M. McFarland, Mai Abdusamad, Carolyn Marquis… in Nature (2021)

  3. Article

    Author Correction: Cas9 activates the p53 pathway and selects for p53-inactivating mutations

    An amendment to this paper has been published and can be accessed via a link at the top of the paper.

    Oana M. Enache, Veronica Rendo, Mai Abdusamad, Daniel Lam… in Nature Genetics (2020)

    Download PDF (854 KB) View Article

  4. No Access

    Article

    Cas9 activates the p53 pathway and selects for p53-inactivating mutations

    Cas9 is commonly introduced into cell lines to enable CRISPR–Cas9-mediated genome editing. Here, we studied the genetic and transcriptional consequences of Cas9 expression itself. Gene expression profiling of ...

    Oana M. Enache, Veronica Rendo, Mai Abdusamad, Daniel Lam… in Nature Genetics (2020)